Barbara J Gitlitz

Barbara J Gitlitz

UNVERIFIED PROFILE

Are you Barbara J Gitlitz?   Register this Author

Register author
Barbara J Gitlitz

Barbara J Gitlitz

Publications by authors named "Barbara J Gitlitz"

Are you Barbara J Gitlitz?   Register this Author

34Publications

959Reads

35Profile Views

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

J Clin Oncol 2018 05 27;36(14):1412-1418. Epub 2018 Mar 27.

Brigette B.Y. Ma, Edwin P. Hui, Kwok-Wai Lo, Ka-Fai To, K.C. Allen Chan, Y.M. Dennis Lo, Ann D. King, and Anthony T.C. Chan, The Chinese University of Hong Kong, Shatin, Hong Kong, Special Administrative Region, People's Republic of China; Wan-Teck Lim, National Cancer Centre; Boon-Cher Goh, National University Cancer Institute of Singapore; Alex Y.C. Chang, Johns Hopkins University School of Medicine; Akhil Chopra, OncoCare Cancer Centre, Singapore; Adam Pettinger, Nathan R. Foster, Charles Erlichman, Jun Yin, and Brian A. Costello, Mayo Clinic, Rochester, MN; Jonathan W. Riess, University of California Davis Comprehensive Cancer Center, Sacramento; Barbara J. Gitlitz, University of Southern California Keck School of Medicine, Los Angeles; Dean W. Lim, City of Hope Comprehensive Cancer Center, Duarte, CA; Mark Agulnik, Northwestern University, Evanston, IL; Julie A. Kish and Christine H. Chung, Moffitt Cancer Center, University of South Florida, Tampa, FL; Douglas R. Adkins, Washington University School of Medicine, St Louis, MO; Kevin J. Cullen, University of Maryland, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.0388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941615PMC
May 2018

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

Lung Cancer 2017 04 9;106:110-114. Epub 2017 Feb 9.

Department of Medicine, Division of Hematology-Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.02.005DOI Listing
April 2017

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Cancer Discov 2016 06 21;6(6):601-11. Epub 2016 Apr 21.

Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee. Addario Lung Cancer Medical Institute, Cambridge, Massachusetts. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893907PMC
June 2016

Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.

J Thorac Oncol 2015 Jan;10(1):110-5

*University of California Davis Comprehensive Cancer Center, Sacramento, California; †SWOG Statistical Center and the Fred Hutchinson Cancer Research Center, Seattle, Washington; ‡Humboldt Medical Specialists, Eureka, California; and §Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320001PMC
January 2015

Eribulin: a new-generation antimicrotubule agent in lung cancer therapy.

Future Oncol 2014 Oct;10(12):1913-24

Keck School of Medicine, Medical Oncology, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.155DOI Listing
October 2014

A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.

J Thorac Oncol 2014 Apr;9(4):577-82

*University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, California; †Providence Cancer Center, Portland, Oregon; ‡University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida; §Ohio State University, Columbus, Ohio; ‖Vanderbilt University, Nashville, Tennessee; and ¶Tragara Pharmaceuticals, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000082DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271824PMC
April 2014

Epigenetic therapy in lung cancer.

Front Oncol 2013 30;3:135. Epub 2013 May 30.

Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California , Los Angeles, CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2013.00135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667274PMC
June 2013

Cell, gene and vaccine based strategies in kidney cancer.

Cancer Treat Res 2003 ;116:183-98

University of California @ Los Angeles, 10945 Le Conte Avenue, Suite 2333, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4615-0451-1_11DOI Listing
May 2004

Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment.

Radiology 2004 May;231(2):359-64

Department of Radiological Sciences, UCLA Medical Center, 10833 Le Conte Ave, B2-168 CHS, Los Angeles, CA 90095-1721, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2312021754DOI Listing
May 2004

A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma.

J Immunother 2003 Sep-Oct;26(5):412-9

Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine at University of California, Los Angeles, 10945 Le Conte Avenue, Suite 2333, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/immunotherapy-journal/2003/0900
Web Search
http://dx.doi.org/10.1097/00002371-200309000-00004DOI Listing
April 2004

Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients.

Int J Cancer 2003 Nov;107(2):256-61

Division of Pulmonary and Critical Care Medicine, UCLA School of Medicine, Los Angeles, CA 90095-1690, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.11379DOI Listing
November 2003

A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.

Cancer 2003 Nov;98(9):1863-9

Division of Hematology/Oncology, University of California-Los Angeles School of Medicine, Los Angeles, California 90033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.11726DOI Listing
November 2003

Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer.

J Immunother 2003 Mar-Apr;26(2):171-8

Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, Los Angeles, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00002371-200303000-00010DOI Listing
September 2003

Cytokine-based therapy for metastatic renal cell cancer.

Urol Clin North Am 2003 Aug;30(3):589-600

Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at University of California, Los Angeles, 2333 PVUB, 10945 Le Conte Avenue, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0094-0143(03)00027-2DOI Listing
August 2003

Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.

J Urol 2003 Jun;169(6):2076-83

Department of Urology, University of California School of Medicine, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.ju.0000066130.27119.1cDOI Listing
June 2003

Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy.

J Urol 2003 Mar;169(3):909-16

Kimmel Cancer Center, Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.ju.0000045706.35470.1eDOI Listing
March 2003

Mathematical model to predict individual survival for patients with renal cell carcinoma.

J Clin Oncol 2002 Mar;20(5):1368-74

Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA 90095-1738, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.20.5.1368DOI Listing
March 2002

Collecting duct renal cell carcinoma: clinical study of a rare tumor.

J Urol 2002 Jan;167(1):71-4

Department of Urology, Division of Urologic Oncology, University of California School of Medicine-Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0022-5347(05)65385-2DOI Listing
January 2002